Penumbra, Inc.
NYSE:PENMedical - Devices
-$2.30 today
- Market cap
- $12.64B
- Beta
- 0.70
- P/E (TTM)
- 72.6
- EPS (TTM)
- $4.36
Volume 0.21M
Average 0.50M
PEN Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Penumbra, Inc.NYSE: PEN
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns positive
Q2 FY2026 accounts payables was $1.39M, compared with -$3.25M a year earlier. Trailing-twelve-month accounts payables was $16.92M. Over 3 fiscal years it compounded at -38.8% a year.
Context
- Accounts payables amounted to 0.2% of revenue in FY2025, down 0.1 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $1.39M or moves back toward the trailing-twelve-month quarterly average of $4.23M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 3.07M USD
- Year-over-year change
- -26.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.07M | -26.5% |
| FY2024 | 2024-12-31 | 4.17M | +280.3% |
| FY2023 | 2023-12-31 | 1.1M | -91.8% |
| FY2022 | 2022-12-31 | 13.39M | +955.3% |
| FY2021 | 2021-12-31 | (1.57M) | — |
Accounts Payables vs competitors
How PEN compares with its peers on the latest reported figures
- PEN's LTM Jun 2026 accounts payables of $16.92M is the 4th largest of the 9 companies compared; the peer median is $3.56M.
- Its year-over-year change of +451.0% is the 2nd highest of 8, against a peer median of -47.4%.
- Accounts payables amounts to 1.1% of revenue for PEN, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $172M | -63.2% | — | 0.8% | |
| LTM Jun 2026 | $171.4M | +532.5% | — | 2.6% | |
| LTM Jul 2026 | $113M | -47.4% | -59.6% | 0.3% | |
| LTM Jun 2026 | $16.92M | +451.0% | -38.8% | 1.1% | |
| LTM Sep 2026 | $13M | -117.2% | +39.6% | 0.1% | |
| LTM Feb 2026 | $10.94M | +42.4% | — | 3.5% | |
| LTM Mar 2026 | $7.12M | +319.4% | +86.7% | 2.8% | |
| LTM Sep 2026 | $2.42M | -131.8% | -56.9% | 0.2% | |
| LTM Jun 2026 | $0 | — | +31.5% | 0.0% | |
| Peer median (excluding PEN) | $3.56M | -47.4% | +31.5% | 0.6% | |
Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.28M | (2M) | 90.95M | 14.01M | 177.69M |
| Depreciation & Amortization | 16.41M | 24.32M | 27.26M | 23.7M | 17.47M |
| Deferred Income Tax | (14.09M) | 1.46M | (19.06M) | (16.34M) | 21.03M |
| Stock-Based Compensation | 0 | 0 | 0 | 46.16M | 59.21M |
| Change in Working Capital | (66.71M) | (121.54M) | (79.08M) | (23.78M) | (42.72M) |
| Accounts Receivables | (21.34M) | (69.86M) | (266K) | 26.6M | (19.51M) |
| Inventory | (51.55M) | (74.63M) | (67.71M) | (65.66M) | (26.48M) |
| Accounts Payables | (1.57M) | 13.39M | 1.1M | 4.17M | 3.07M |
| Other Working Capital | 7.75M | 9.57M | (12.21M) | 11.11M | 213K |
| Other Non-Cash Items | 68.61M | 42.1M | 77.27M | 124.72M | 5.97M |
| Operating Cash Flow | 9.5M | (55.66M) | 97.33M | 168.48M | 238.66M |
| Capital Expenditures | (21.18M) | (19.3M) | (15.21M) | (21.18M) | (63.73M) |
| Acquisitions (Net) | 2.92M | 0 | (988K) | 0 | 0 |
| Purchases of Investments | (126.79M) | 0 | (81.94M) | (32.91M) | (355.74M) |
| Sales of Investments | 123.72M | 74.09M | 82.57M | 130.62M | 14.88M |
| Other Investing Activities | (400K) | 0 | (500K) | 1.1M | 0 |
| Investing Cash Flow | (21.74M) | 54.79M | (16.08M) | 77.62M | (404.59M) |
| Debt Repayment | (1.45M) | (1.75M) | (1.98M) | (2.28M) | (2.49M) |
| Common Stock Issued | 18.37M | 21.55M | 20.41M | 17.17M | 31.82M |
| Common Stock Repurchased | 0 | 0 | 0 | (100.39M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (16.08M) | (8.18M) | (2.23M) | (1.52M) | (2.8M) |
| Financing Cash Flow | 836K | 11.62M | 16.2M | (87.01M) | 26.53M |
| Effect of Forex Changes | 1.11M | (272K) | 168K | (2.18M) | 1.89M |
| Net Change in Cash | (10.29M) | 10.48M | 97.63M | 156.92M | (137.51M) |
| Free Cash Flow | (11.68M) | (74.96M) | 82.12M | 147.3M | 174.93M |
Penumbra, Inc.
NYSE:PEN
Intrinsic Alpha fair value
Locked
Current Price
$320.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.